Compare Gap Inc (GAP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs TG Therapeutics Inc — how do they compare? Gap Inc trades at $21 (market cap $7.55B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Gap Inc and TG Therapeutics Inc are close in size by market cap, and Gap Inc pays a 3.34% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GAP | TGTX | |
|---|---|---|
Market Cap | $7.55B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $59.06 |
52-Week Low | $18.35 | $26.94 |
Enterprise Value | $10.63B | $7.84B |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap's stock trades at $20.22, down 6% today, yet maintains a bullish technical signal with strong moving averages. Fundamentally, the company shows robust profitability with a 40.5% gross margin and 27.58% ROE, supported by recent earnings beats. Revenue has stabilized around $15B after a 2023 dip, with net income climbing to $844M in 2025. Positive analyst sentiment is evident with a $26.09 consensus target, though recent news includes an ongoing legal investigation.
The outlook for Gap is cautiously optimistic, with valuation metrics like a P/E of 8.32 suggesting potential upside. Key opportunities include continued margin expansion and digital transformation efforts, while risks involve competitive pressures and the outcome of regulatory scrutiny. The stock's current price near the low end of analyst targets may attract value investors seeking turnaround momentum.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
